625 related articles for article (PubMed ID: 22782963)
41. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer.
Rosenblatt R; Sherif A; Rintala E; Wahlqvist R; Ullén A; Nilsson S; Malmström PU;
Eur Urol; 2012 Jun; 61(6):1229-38. PubMed ID: 22189383
[TBL] [Abstract][Full Text] [Related]
42. Shorter recurrence-free survival time, higher risk of multiple recurrences: a retrospective study of non-muscle invasive bladder cancer after transurethral resection.
Deng N; Chen JX; Chen LW; Qiu SP; Li XF; Wang DH
Chin Med J (Engl); 2012 Oct; 125(20):3681-6. PubMed ID: 23075724
[TBL] [Abstract][Full Text] [Related]
43. Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials.
Fernandez-Gomez J; Solsona E; Unda M; Martinez-Piñeiro L; Gonzalez M; Hernandez R; Madero R; Ojea A; Pertusa C; Rodriguez-Molina J; Camacho JE; Isorna S; Rabadan M; Astobieta A; Montesinos M; Muntañola P; Gimeno A; Blas M; Martinez-Piñeiro JA;
Eur Urol; 2008 May; 53(5):992-1001. PubMed ID: 17950987
[TBL] [Abstract][Full Text] [Related]
44. Risk factors for intravesical recurrence in patients with high-grade T1 bladder cancer in the second TUR era.
Takaoka E; Matsui Y; Inoue T; Miyazaki J; Nakashima M; Kimura T; Oikawa T; Kawai K; Yoshimura K; Habuchi T; Ogawa O; Nishiyama H
Jpn J Clin Oncol; 2013 Apr; 43(4):404-9. PubMed ID: 23444116
[TBL] [Abstract][Full Text] [Related]
45. Prognostic value of Bcl-2 and Bax tumor cell expression in patients with non muscle-invasive bladder cancer receiving bacillus Calmette-Guerin immunotherapy.
Ajili F; Kaabi B; Darouiche A; Tounsi H; Kourda N; Chebil M; Manai M; Boubaker S
Ultrastruct Pathol; 2012 Feb; 36(1):31-9. PubMed ID: 22292735
[TBL] [Abstract][Full Text] [Related]
46. Intravesical therapy for bladder cancer.
Williams SK; Hoenig DM; Ghavamian R; Soloway M
Expert Opin Pharmacother; 2010 Apr; 11(6):947-58. PubMed ID: 20205607
[TBL] [Abstract][Full Text] [Related]
47. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience.
Efstathiou JA; Spiegel DY; Shipley WU; Heney NM; Kaufman DS; Niemierko A; Coen JJ; Skowronski RY; Paly JJ; McGovern FJ; Zietman AL
Eur Urol; 2012 Apr; 61(4):705-11. PubMed ID: 22101114
[TBL] [Abstract][Full Text] [Related]
48. Prognostic impact of angiogenesis in nonmuscle invasive bladder cancer as defined by microvessel density after immunohistochemical staining for CD34.
Ajili F; Kacem M; Tounsi H; Darouiche A; Enayfer E; Chebi M; Manai M; Boubaker S
Ultrastruct Pathol; 2012 Oct; 36(5):336-42. PubMed ID: 22574784
[TBL] [Abstract][Full Text] [Related]
49. Rapidly alternating chemotherapy and radiotherapy instead of cystectomy for the treatment of muscle-invasive carcinoma of the urinary bladder: long term results of a pilot study.
Vikram B; Chadha M; Malamud SC; Hecht H; Grabstald H
Cancer; 1998 Mar; 82(5):918-22. PubMed ID: 9486582
[TBL] [Abstract][Full Text] [Related]
50. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer.
Freiha F; Reese J; Torti FM
J Urol; 1996 Feb; 155(2):495-9; discussion 499-500. PubMed ID: 8558644
[TBL] [Abstract][Full Text] [Related]
51. Cigarette smoking status at diagnosis and recurrence in intermediate-risk non-muscle-invasive bladder carcinoma.
Serretta V; Altieri V; Morgia G; Di Lallo A; Carrieri G; Allegro R;
Urology; 2013 Feb; 81(2):277-81. PubMed ID: 23374781
[TBL] [Abstract][Full Text] [Related]
52. Prognostic significance of adjuvant cisplatin-based combination chemotherapy following radical cystectomy in patients with invasive bladder cancer.
Muramaki M; Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Int J Urol; 2008 Apr; 15(4):314-8. PubMed ID: 18380818
[TBL] [Abstract][Full Text] [Related]
53. Intra-arterial chemotherapy combined with intravesical chemotherapy compared with intravesical BCG immunotherapy retrospectively in high-risk non-muscle-invasive bladder cancer after transurethral resection of the bladder tumor.
Huang B; Huang G; Li W; Chen L; Mao X; Chen J
J Cancer Res Clin Oncol; 2021 Jun; 147(6):1781-1788. PubMed ID: 33222014
[TBL] [Abstract][Full Text] [Related]
54. Bladder preservation multimodality therapy as an alternative to radical cystectomy for treatment of muscle invasive bladder cancer.
Maarouf AM; Khalil S; Salem EA; ElAdl M; Nawar N; Zaiton F
BJU Int; 2011 May; 107(10):1605-10. PubMed ID: 20825396
[TBL] [Abstract][Full Text] [Related]
55. Pretreatment proliferation and local control in bladder cancer after radiotherapy with or without concurrent chemotherapy.
Weiss C; Rödel F; Ott O; Engehausen DG; Papadopoulos T; Sauer R; Rödel C
Strahlenther Onkol; 2007 Oct; 183(10):552-6. PubMed ID: 17896086
[TBL] [Abstract][Full Text] [Related]
56. Intravesical mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the bladder.
Halachmi S; Moskovitz B; Maffezzini M; Conti G; Verweij F; Kedar D; Sandri SD; Nativ O; Colombo R
Urol Oncol; 2011; 29(3):259-64. PubMed ID: 19395285
[TBL] [Abstract][Full Text] [Related]
57. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.
Peyromaure M; Guerin F; Amsellem-Ouazana D; Saighi D; Debre B; Zerbib M
J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729
[TBL] [Abstract][Full Text] [Related]
58. The role of combined method in organ-sparing treatment of muscle-invasive bladder cancer recurrences.
Startsev VY
Arch Ital Urol Androl; 2002 Jun; 74(2):54-6. PubMed ID: 12161935
[TBL] [Abstract][Full Text] [Related]
59. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED
J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
[TBL] [Abstract][Full Text] [Related]
60. [Superficial bladder tumors. Results of preventive treatment of recurrence by intravesical instillation of BCG].
Charbit L; Tremeaux JC; Cukier J
Ann Med Interne (Paris); 1989; 140(8):695-7. PubMed ID: 2629569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
